LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Amino Acids Predict Prognosis in Patients with Acute Dyspnea

By LabMedica International staff writers
Posted on 15 Nov 2021
Print article
Image: The AVANCE III, 500 MHz spectrometer has a room temperature QXI probe, triple axis gradients, temperature controller and automatic tuning (Photo courtesy of University of Idaho)
Image: The AVANCE III, 500 MHz spectrometer has a room temperature QXI probe, triple axis gradients, temperature controller and automatic tuning (Photo courtesy of University of Idaho)
The main symptom of dyspnea is labored breathing. It may last for a minute or two after strenuous activity or it could be a chronic problem. One of the most common symptoms in the emergency departments (ED) is dyspnea, presented in roughly 3 to 4 million annual ER visits in the USA.

Chronic cardiorespiratory diseases, which underlie susceptibility to episodes of acute dyspnea, and acute events leading to an exacerbation, pose severe challenges to the body and result in metabolic changes, often mediated by the release of stress hormones. The severity of the disease state in patients with acute dyspnea may also be related to increased levels of specific amino acids.

Clinical Scientists at Lund University (Malmo, Sweden) included in a study, 663 patients to identify amino acids that can predict risk of 90-day mortality in patients with acute dyspnea. Blood pressure, oxygen saturation and heart rate were measured using a fully automated oscillometric device (CARESCAPE Monitor B850 or B650, General Electric Healthcare, Chicago, IL, USA).

Plasma concentration of C-reactive protein (CRP), lactate and creatinine was measured using an ABL800 Flex machine (Radiometer, Crawley, UK) or Afinion AS100 Analyzer System (Abbott, Abbott Park, IL, USA). Frozen serum samples were analyzed using a proton nuclear magnetic resonance (NMR) platform, the AVANCE III, 500 MHz spectrometer (Bruker, Billerica, MA, USA), which included nine selected amino acids chosen for revision in the study.

The investigators reported that during the 90 days of follow-up, 80 patients died, 69 of whom had been admitted to a ward upon their arrival in the ED, and six patients died in the ED. An “Amino Acid Mortality Risk Score” (AMRS), summing absolute plasma levels of glycine, phenylalanine and valine, demonstrated that among the patients belonging to quartile 1 (Q1) of the AMRS, only four patients died, compared to 44 patients in quartile 4. Using Q1 of the AMRS as reference, each increment of 1 SD in the AMRS was associated with a hazard ratio (HR) of 2.15 for 90-day mortality, and the HR was > 9 times higher in Q4.

The authors concluded that glycine, phenylalanine and valine are associated with the risk of 90-day mortality in patients admitted to the ED with a primary symptom of acute dyspnea. A score using these amino acids may guide in risk assessment, supporting decision making processes to establish appropriate level of care and treatment intensity. The study was published on October 30, 2021 in the journal BMC Emergency Medicine.

Related Links:
Lund University
General Electric Healthcare
Radiometer
Abbott
Bruker


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more